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bstract
bjective:  The purpose of this article is to provide a comprehensive overview of imaging findings in patients with hepatic fibrosis and cirrhosis;
nd to describe which radiological/clinical modality is best for staging hepatic fibrosis.
onclusion:  MR elastography (MRE) appears to be the most reliable method for grading liver fibrosis, although the CT fibrosis score derived
rom the combination of caudate-to-right-lobe ratio and the diameters of the liver veins significantly correlates with the stage of fibrosis.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/4.0/).
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.  Introduction
Hepatic cirrhosis is the pathological sequela of all chronic
iver diseases [1]. The most common causes of hepatic cirrho-
deficiency, Wilson’s disease, biliary cirrhosis and cardiac cir-
rhosis. Chronic inflammation leads to potentially reversible liver
fibrosis and ends in irreversible cirrhosis with the cross-linking
of collagen fibres and the formation of regenerative nodules.is are alcoholic fatty liver disease (AFLD), non-alcoholic fatty
iver disease (NAFLD) and viral hepatitis [2]. Less frequent
auses of cirrhosis are haemochromatosis, alpha1-antitrypsin
∗ Corresponding author. Tel.: +41 31 632 19 65; fax: +41 31 632 48 74.
E-mail addresses: andreas.christe@insel.ch, andreas.christe@hotmail.com
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352-0477/© 2015 The Authors. Published by Elsevier Ltd. This is an open ac
icenses/by-nc-nd/4.0/).athologists routinely distinguish patterns of predominantly
ericentral fibrosis (e.g., in AFLD/NAFLD fibrosis/cirrhosis)
3] from patterns of predominantly periportal fibrosis (e.g., in
hronic viral hepatitis, autoimmune hepatitis or biliary disease-
nduced fibrosis/cirrhosis) [4]. The fibrotic stage is classified
ccording to histological criteria using the METAVIR scoring
ystem whereby stages F1–F4 predominantly assess periportal
brosis [5] and stages B1–B4 predominantly assess pericentral
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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brosis [6]. Because the two staging systems differ only in the
brosis pattern (which depends on the aetiology of the fibro-
is), the resultant data are comparable in terms of the severity
f fibrosis (both stages 1 to 4). A liver with stage 4 fibrosis is
quivalent to a cirrhotic liver.
All aetiologies of liver cirrhosis lead to the same pro-
ess, namely macroscopic parenchymal changes and secondary
hanges due to portal hypertension. The difference in portal
lood supply is thought to be responsible for the atrophy of
he left lobe and hypertrophy of the right lobe: the right lobe
s fed by the right portal vein which is haemodynamically sup-
lied by the superior mesenteric vein, which drains the upper GI
ract and contains higher concentrations of alcohol and toxins
han the lower GI tract [7]. The inferior mesenteric vein with
lood from the lower GI tract mainly supplies the left portal
ein and the left and caudate lobes of the liver. A small cadaver
tudy revealed that the right lobe was more fibrotic than the cau-
ate lobe [8]. The disease process characterised by right lobe
trophy and left lobe hypertrophy is described by the modified
audate-to-right-lobe ratio described by Awaya et al. [9]. Later in
he fibrosis/cirrhosis sequence, liver heterogeneity and a nodu-
ar surface associated with regeneration processes appear; these
hanges are more easily detectable radiologically following con-
rast administration [10–12]. This repair process results not only
n the formation of regenerative nodules but also in the com-
ression of the central liver veins. A right liver vein below 7 mm
n diameter should raise suspicion for cirrhosis [13]. Indirect
hanges associated with portal hypertension occur relatively late
n the development of cirrhosis and include dilation of the hepatic
ortal vein to a diameter greater than 14 mm, splenomegaly
>11 cm longitudinal axis distance), porto-systemic collateral
essels (recanalisation of the umbilical vein, gastro-spleno-renal
ollateral vessels, gastro-oesophageal varices and even rectal
arices), ascites and thickening of the bowel walls [14–16]. Rou-
ine biochemical and haematological tests are unable to quantify
iver fibrosis in approximately 50% of patients [17]. An early
iagnosis of liver fibrosis can improve the benefit of early ther-
peutic interventions prior to the development of irreversible
nd potentially fatal complications such as loss of liver func-
ion, oesophageal variceal bleeding, hepatic encephalopathy and
epatocellular carcinoma [18]. Approximately 80% of all hepa-
ocellular carcinomas (HCC) arise from an underlying cirrhotic
iver [19].
.  Radiological  examinations
.1.  Ultrasonography
The accuracy, sensitivity and specificity of regular B-mode
onography for diagnosing liver cirrhosis have been reported
o be 64–79%, 52–69% and 74–89%, respectively [20–22]. An
rregular or nodular surface and blunt edges or morphological
hanges in the liver are the most specific signs of cirrho-
is on ultrasound (Figs. 1–4). Contrast-enhanced ultrasound
ith sulphur hexafluoride-filled micro-bubbles covered with a
hospholipid shell may more easily detect HCC (+20%) than
irrhosis [23].
i
c
t
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Considerable efforts have been devoted to detecting liver
irrhosis noninvasively. An inexpensive and simple approach
s sonographic elastography [24], a noninvasive and reli-
ble method of detecting liver cirrhosis. Two techniques for
onographic elastography have been described: transient elas-
ography (Fibroscan) and acoustic radiation force impulse
ARFI) elastography. The area under the receiver operating
haracteristic (ROC) curve of Fibroscan and ARFI elastogra-
hy ranges from 0.85 to 0.91 for cirrhosis (fibrosis stage 4) and
evere fibrosis (fibrosis stage 3); for moderate fibrosis (fibrosis
tages 1 and 2), Fibroscan produces significantly better results
han ARFI elastography, with areas under the ROC curve of 0.88
nd 0.81, respectively (p  = 0.008). However, in 2–11% of cases,
iver failure is not diagnosed with Fibroscan [25,26]. Another
imitation of these techniques is that only a very small volume
f the liver can be measured at one time and the accuracy of
his measurement is very operator-dependent [27]. The useful-
ess of these techniques is also limited in obese patients and
n patients with ascites, both of which are situations that often
ccur in patients with hepatic fibrosis [28]. In the case of obese
atients, the area under the ROC curve for both Fibroscan and
RFI elastography drops to 0.63.
In conclusion, sonographic elastography is an inexpensive
nd accurate method of diagnosing hepatic cirrhosis. However,
his approach is operator-dependent and of limited usefulness
or detecting early pre-cirrhotic stages of liver fibrosis in cases
f inhomogeneous fibrosis, in obese patients and in patients with
scites.
.2.  Computer-tomography  (CT)
Abdominal CT scans are increasingly performed in rou-
ine clinical studies in hospitals and radiology institutes. A
areful examination of the liver parenchyma and a thorough
creening for fibrosis in CT scans is mandatory, particularly
or patients with no suspected liver pathology. Numerous char-
cteristic imaging findings associated with liver cirrhosis have
een described; however, the diagnostic accuracy of CT scans
emains disappointing. Imaging findings suggestive of liver cir-
hosis include an irregular or nodular hepatic surface, a blunt
iver edge, parenchymal abnormalities, morphological changes
n the liver and manifestations of portal hypertension (Figs. 5–8).
n a multicentre study conducted by Kudo et al., the diagnostic
ccuracy, sensitivity and specificity of CT for hepatic cirrhosis
ere 67–86%, 77–84% and 53–68%, respectively [20,29].
Harbin et al. developed a cirrhosis score for transverse imag-
ng using the ratio of the width of the transverse caudate lobe to
he width of the transverse right lobe. The sensitivity, specificity
nd accuracy of this score for detecting cirrhotic livers were
4%, 100% and 94%, respectively. A relative widening of the
orta hepatis was sensitive but not specific for liver cirrhosis [8]
Fig. 5).
Few studies have investigated the accuracy of CT findings
n pre-cirrhotic liver fibrosis. Measures such as the modified
audate-to-right-lobe ratio [9] and a decrease in the diameter of
he liver vein [13] have been used to detect liver remodelling on
R images. The combination of both of these variables (i.e., the
92 A. Huber et al. / European Journal of Radiology Open 2 (2015) 90–100
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Cig. 1. (A) Liver cirrhosis in ultrasonography: inhomogeneous liver parenchy
ilation of portal vein, splenomegaly (C) and collateral vessels within the abdom
um of liver vein diameters divided by the caudate-to-right-lobe
atio) has been used as a CT fibrosis score with a sensitivity of
3% and a specificity of 76% for pre-cirrhotic liver fibrosis [30]
Fig. 6) and a sensitivity of 88% and specificity of 82% for liver
c
a
a
ig. 2. Ultrasonography of a 25-year-old patient suffering from haemochromatosis. (
audate lobe is enlarged (asterisk, sagittal plane). (C) Splenomegaly 17 cm. (D) Hepsterisk) with surface nodularity (arrow). (B) Portal venous hypertension with
 wall (D).
irrhosis. This score represents a new way of diagnosing pre-
irrhotic liver fibrosis and an improvement over the diagnostic
bility of CT scans for liver cirrhosis (sensitivity of 77–84%
nd specificity of 53–68% for CT [20]). Other imaging findings
A) Inhomogenous liver parenchyma with surface nodularity (white arrow). (B)
atofugal flow in the left portal vein (stream inversion).
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Sig. 3. Ultrasonography of a 64-year-old male patient suffering from Laennec’s c
f the liver with compression of the middle hepatic vein (6 mm diameter), note 
ssociated with hepatic cirrhosis and their ability to differen-
iate between normal hepatic fibrosis and cirrhosis are listed in
able 1. The fibrosis score derived from the combination of these
wo variables was shown to correlate significantly with the grade
f fibrosis obtained by CT [30].
CT scans could be used to screen for liver fibrosis and jus-
ify the use of more accurate diagnostic methods. In particular,
atients with a potentially reversible stage of liver fibrosis could
enefit from an early diagnosis and early initiation of therapy.
c
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d
ig. 4. Ultrasonography of a 64-year-old female patient suffering from hepatitis C 
umbilical vein, white arrow), dilated main portal vein (black arrow, 19 mm). (C) G
ubhepatic collateral veins.sis. (A) Regular hepatopetal blood flow in the right portal vein. (B) Remodelling
CC in the periphery of the liver (white arrow).
One limitation of diagnostic CT is the dose of radiation asso-
iated with its use. Technical improvements in CT technology,
ncluding the use of automated CT tube current modulation, care
oltage, new image reconstruction algorithms (iterative recon-
truction) and the latest generation of CT detectors in which
lectronics and the photodiode are combined into a single unit
ould reduce the dose of radiation used in a diagnostic abdomi-
al scan by more than 50%. Nevertheless, the average equivalent
ose of an abdominal scan is approximately 5 mSv (millisievert),
induced cirrhosis. (A) Hyperechoic fatty liver. (B) Massive collateral vessels
astrolienal collateral veins and splenomegaly. (D) Dilated umbilical vein. (E)
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Fig. 5. (A, B) CT of liver cirrhosis with right lobe atrophy and left lobe hypertrophy complex with a caudate (arrow) to right (asterisk) lobe ratio >1. (C) Right vein
diameter <7 mm due to compression of cirrhotic liver parenchyma; note additional gynecomasty (asterisk). (D) Signs of portal venous hypertension with recanalisation
of umbilical vein and therefore no extensive splenomegaly (asterisk).
Fig. 6. Pathologic caudate–right-lobe ratio (CRL) in a patient with pre-cirrhotic
liver fibrosis (CT): hypertrophy of the left and atrophy of the right liver. In axial
planes a line parallel to the midsagittal plane was drawn through the right lateral
wall of the first bifurcation of the right portal vein. Distances perpendicular to
the drawn line to the most medial margin of the caudate lobe and the lateral
margin of the right lobe midway between the main portal vein and the inferior
caval vein were measured. The two distances were divided (caudate lobe/right
lobe) and defined as the caudate–right-lobe ratio (CRL). The sum of liver vein
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sis to 88% and 85%, respectively, by measuring the diameteriameters (LD) equals 7.8 mm. LD divided by CRL equals the CT fibrosis score,
hich is below 20 and therefore compatible with liver cirrhosis.
hich corresponds to a risk of radiation-induced cancer death
f 1/5000 per CT scan [31–33].
Until now, the measurement of liver stiffness by CT had
ot been possible because of the potentially harmful dose of
adiation and the availability of the radiation-free alternatives
onography and MR. The advantage of CT imaging lies in its
o
a
bbility to rapidly detect HCC and perform staging following
ontrast injection [34,35].
.3.  Magnetic  resonance  imaging
Surface nodularity, heterogeneous enhancement, a small liver
ize, caudate lobe enlargement, splenomegaly, a decreased right-
o-left-lobe-volume ratio, varices, an expanded gallbladder fossa
36,37], a posterior notch and ascites [38] are well known
eatures of liver cirrhosis [13] (Figs. 9–12). Nevertheless, the
ensitivity and specificity of classic contrast-enhanced MRI for
iver cirrhosis are 87% and 54%, respectively, which are sim-
lar to the sensitivity and specificity of CT [20]. Awaya et al.
bserved that the hypertrophied portion of the right lobe of the
iver appears to extend beyond the bifurcation of the main por-
al vein (Harbin’s caudate-to-right-lobe ratio) and to the right
ateral edge of the ligamentum venosum where the right portal
ein bifurcates (modified caudate-to-right-lobe ratio or CRL).
n the case of a CRL greater than 0.90, the sensitivity, speci-
city and accuracy of MR imaging for cirrhosis were 71.7%,
7.4% and 74.2%, respectively. In contrast, the maximum accu-
acy achieved with Harbins’s CRL was 65.7%. Only the modified
RL enabled these authors to find significant differences in the
atios of the three Child–Pugh classes [9]. Zhang et al. were
ble to increase the sensitivity and specificity for liver cirrho-f hepatic veins only, as the regenerative nodules and fibrosis
ssociated with cirrhosis tend to compress the hepatic veins; the
est cut-off diameter for the right hepatic vein was 7 mm [13].
A. Huber et al. / European Journal of R
Fig. 7. CT of a 58-year-old female patient with alcoholic liver cirrhosis. Large
collateral vessels (black arrows): re-opened umbilical vein (A), gastro-lienal col-
laterals (B). Because of the re-opening of the umbilical vein the spleen (asterisk)
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raphy has a sensitivity of 98% and specificity of 99% [51] andsually does not enlarge. Note the nodularity of the liver surface (white arrow).
MR elastography [39], double contrast-enhanced MRI [40],
iffusion-weighted MRI [41], susceptibility-weighted MRI
42,43] and T1rho [44] are able to detect liver fibrosis in a pre-
irrhotic stage with great accuracy. Double-contrast MRI uses
uperparamagnetic iron oxide (SPIO) particles that accumulate
n hepatic Kupffer cells and lead to a shortening of the T2*
elaxation time, producing a dark liver background. By com-
arison, gadolinium-based contrast media leads to a delayed
nhancement of the septal and bridging fibrosis [40]. Both con-
rast agents facilitate the visualisation of early fibrosis and the
ifferentiation of advanced hepatic fibrosis from mild or absent
brosis with an accuracy of 93% [45].
Fibrotic tissue restricts the diffusion of water molecules.
onsequently, diffusion-weighted imaging should depict differ-
nt stages of fibrosis (Fig. 9); however, inconsistent results for
taging liver fibrosis have been reported [17,41,46]. The sensi-
ivity and specificity of diffusion-weighted MRI with single-shot
cho-planar technique using a hepatic apparent diffusion coef-
2cient (ADC) at b values of 50, 300, 500, 700, and 1000 s/mm
ave been reported to be up to 83% and 89%, respectively, for
tage 2 fibrosis or greater [41]. These results may vary because
i
s
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he ADC is dependent on perfusion, hepatic steatosis, hepatic
ron stores and hepatic inflammation [40].
Susceptibility-weighted MRI (SWI) is a 2D GRE-based SWI
equence [42] that detects small amounts of paramagnetic mate-
ial due to their faster relaxation time. This sequence has been
sed to detect the deposition of paramagnetic iron in cerebral
aemorrhages. In a fibrotic liver, small amounts of iron that can
e detected by SWI are always present in regenerative nodules.
he loss in the paramagnetic signal is proportional to the degree
f liver remodelling. The liver-to-muscle signal intensity (SI)
atio is strongly correlated with fibrosis, moderately correlated
ith inflammatory activity and iron load and not correlated with
teatosis. The liver-to-muscle-SI ratio performed well in terms
f grading liver fibrosis, with a sensitivity and specificity of 98%
nd 82%, respectively, for scores of F2 or higher and 80% and
9%, respectively, for a score of F4 (liver cirrhosis) [43].
T1rho is another promising MR technique used to diagnose
iver fibrosis. This approach measures the relaxation of motion-
estricted water molecules and their local macromolecular
nvironment (e.g., proteoglycan or collagen in the extracellular
atrix). T1rho values are prolonged with the accumulation of
ompounds in the extracellular matrix [47]. Mean liver T1rho
alues greater than 50 ms using a 2D TurboFLASH sequence
ith spin-lock preparation are associated with a sensitivity and
pecificity of 90.5% and 90%, respectively [44].
MR elastography (MRE) appears to be the most reliable of
hese new MRI-based methods [48]. MRE analyses the propaga-
ion of mechanical waves through tissue [49]. The velocity and
avelength of these waves increase with greater tissue stiffness
50]. Thus, images of the propagating waves can be used to esti-
ate tissue stiffness. Motion-sensitising gradients are applied
uring the acquisition of the image. The gradients are similar to
hose applied in phase-contrast MR angiography and diffusion-
eighted imaging [40]. Patients are placed in the supine position
ith a pneumatic driver placed over the liver on the anterior
bdominal wall. The pneumatic driver generates mechanical
aves by vibrating at low frequencies (40–120 Hz). The waves
ropagating into the liver are measured with a MRI-protocol
ith 2D gradient-echo sequences and cyclic motion-encoding
radients (MEG). Specialised computer-based algorithms ana-
yse these mechanical waves. Quantitative images measuring
hear stiffness (MR elastograms) are generated and liver stiffness
s calculated in kPa. Yin et al. showed that MR elastography with
 shear stiffness cut off value of 2.93 kPa had a sensitivity of 98%
nd a specificity of 99% for diagnosing any grade of liver fibrosis
grades 1–4) [51]. MR elastography appears to be highly accu-
ate for detecting fibrosis early and measuring the stiffness of the
ntire liver. Salameh et al. showed that MR elastography accu-
ately measured liver stiffness in rats with steatohepatitis even
efore they developed hepatic fibrosis according to histological
riteria [52]. MRE could be used to differentiate nonalcoholic
atty liver disease (NAFLD) from nonalcoholic steatohepatitis
NASH) before patients develop liver fibrosis [53]. MR elastog-s being discussed as an alternative to liver biopsy as the gold
tandard for diagnosing and monitoring liver fibrosis; indeed,
RE is highly accurate, non-invasive and can measure the entire
96 A. Huber et al. / European Journal of Radiology Open 2 (2015) 90–100
Fig. 8. CT of a 57-year-old female patient, suffering from alcoholic liver cirrhosis. (A) Native phase without contrast. (B) Late arterial phase. (C) Portal venous phase.
(D) Equilibrium phase. Atrophic liver with ascites is evident. Early nodular enhancement is depictable in the arterial phase (white arrow, B), there is no wash-out
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Bf this liver nodule, compatible with a regenerative or dysplastic nodule, HCC 
hown (black arrow). Ascites on all slices is evident (asterisk).
epatic volume, whereas a liver biopsy only evaluates a small
olume of the liver and is dependent on the quality of the biopsy
nd the experience of the pathologist. Elasticity cutoff values
nd corresponding areas under the receiver operating character-
stic curves have been described for the different stages of liver
brosis [54]; stages F1–F4 correspond to elasticity cutoff values
f 2.84, 3.18, 3.32 and 4.21 kPa, respectively, and areas under
he ROC curve of 0.91, 0.92, 0.97 and 0.99, respectively. MR
lastography has been shown to have greater sensitivity (at least
s
H
h
able 1
rea under the receiver operating characteristic (ROC) curve of CT predictors for liv
Cirrhotic versus normal liver
(signs of cirrhosis)
AUC 
ight hepatic vein diameter 0.86 
iddle hepatic vein diameter 0.82 
eft hepatic vein diameter 0.85 
um of all hepatic vein diameters (LD) 0.88 
audate-to-right lobe ratio (CRL) 0.82 
T fibrosis score: LD/CRL 0.89 
plenic diameter 0.88 
ortal diameter 0.64 
scites 0.78 
ollateral vessels 0.86 
iver nodularity 0.87 
UC, area under the curve (receiver operating characteristic analysis).
est discriminators have bold values.s probable. Other regenerative nodules with the same enhancement pattern are
% higher) and much more specificity (at least 15% greater)
han DWI for each stage of fibrosis [55].
MR elastography is also preferable to US elastography
ecause an acoustic window is not needed, obese patients can
e reliably examined and no observer variability exists. In addi-
ion, the entire liver can be assessed with MRE, whereas only
mall regions of interest can be viewed with US elastography.
owever, MR elastography is of limited value in patients with
epatitis or cardiac congestion or in patients with increased
er fibrosis and cirrhosis [30].
Fibrotic versus normal liver
(signs of fibrosis)
Cirrhotic versus
fibrotic liver
AUC AUC
0.74 0.64
0.71 0.62
0.77 0.62
0.79 0.65
0.72 0.66
0.82 0.69
0.76 0.66
0.58 0.59
0.55 0.66
0.58 0.73
0.69 0.68
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Fig. 9. Liver cirrhosis in MRI. (A) T2 haste sequence: nodular liver surface (white arrow) with hypertrophic caudate lobe (asterisk) and splenomegaly (black arrow).
(B) T1 vibe fat saturated post-gadolinium image displays the inhomogeneous liver parenchyma with many hypovascular regenerative nodules (white arrow) and
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iver signal (asterisk) compared to a normal liver MRI. (E) Diffusion weighte
DC-maps of normal liver with brighter signal than the cirrhotic liver (D).
epatic iron stores, as these conditions introduce signal-to-noise
imitations, making wave visualisation impossible [27,49,51].
.4.  High-resolution  multifrequency  MRE
Multifrequency MRE is preferable for detecting liver fibro-
is because monofrequency MRE produces standing waves with
on-undulating wave nodes that do not permit elastographic
easurement. As a result, the special resolution is very low and
nly the stiffness of the entire liver can be measured. This limita-
ion can be overcome with multifrequency MRE; this technique
nables the definition of a high-resolution map of liver stiff-
ess, delivering exact 3D data and allowing the analysis of focal
brosis and the evaluation of focal liver lesions [56].
MRE has been successfully used to diagnose diastolic dys-
unction by identifying abnormalities in myocardial relaxation
57]. Elasticity scores of healthy kidneys and spleens that could
T
s
s
ious intensity of the liver. (D) Ep2d diffusion ADC-maps displays hypointense
ge b800 of a normal liver with homogeneous liver signal. (F) Ep2d diffusion
e used to detect focal fibrotic disease have recently been
ublished [56]. Neurodegenerative processes could also be diag-
osed using MRE imaging of the brain in patients with multiple
clerosis [58].
.5.  Laboratory
CT scans can be used to screen for liver fibrosis and justify
he use of more accurate diagnostic methods such as first-line
erologic testing and the well-established and easily performed
ibroscan. The most important laboratory tests of liver function
re serum aspartate aminotransferase, alkaline phosphatase, ala-
ine aminotransferase and -glutamyl transpeptidase activity.
he activity of all of these parameters has been shown to be
ignificantly altered in cases of mild, moderate and severe fibro-
is (p  = 0.01–0.05); however, in a multiple regression analysis
ncluding the aforementioned parameters and SWI, only SWI
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rterial phase. (C) Portal venous phase. (D) Equilibrium phase. Early HCC enh
he contrast media in the later phases (C, D). Surface nodularity (black arrow) an
roved to be independently associated with increasing fibrosis
cores [43]. Degos et al. [59] showed that Fibroscan could more
eliably detect the stage of fibrosis in patients with chronic viral
epatitis than a biomarker (Hepascore, APRI, Fibrotest®, and
ibrometre®).
.6.  BiopsyA liver biopsy is currently the gold standard for diagnos-
ng liver cirrhosis. However, it entails an invasive procedure
[
D
ig. 11. MRI of a 48-year-old female patient suffering from hepatitis B and C. Cor
idneys (B). Small atrophic right liver with a cranio-caudal distance of 10 cm and prod HCC. (A) T1 weighted fat saturated native phase without contrast. (B) Late
ent is demonstrated in the arterial phase (white arrow, B), there is wash-out of
ertrophy of the caudate lobe (asterisk) with atrophy of the right liver is evident.
nd often produces biased results because very small speci-
ens are taken (only 1/50,000th of the liver is analysed) and
ecause sampling errors and inter-rater variability can occur
27]. The limited number of locations where the biopsy can be
erformed and the associated risks of infection and haemorrhage
re the main disadvantages of an invasive biopsy. Biopsies have
orbidity and mortality rates of 3% and 0.03%, respectively60].
According to the American Association for the Study of Liver
iseases, only patients with substantial liver fibrosis (F2 and
onal T2 haste fat saturated images at the level of the gall bladder (A) and the
minent left liver (asterisk) with splenomegaly (17.5 cm).
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Fig. 12. Pathologic caudate–right-lobe ratio (CRL) in a patient with hepatitis B induced liver cirrhosis (MRI, T2 weighted haste): hypertrophy of the left and atrophy
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[istances of the caudate lobe (C) and right lobe (R) were divided and defined as
quals 12.1 mm. LD divided by CRL equals the CT fibrosis score, which is belo
reater) are eligible for antiviral therapy; therefore, establishing
he exact grade of fibrosis is essential.
.  Conclusion
Liver fibrosis and cirrhosis are increasingly common in
atient populations with a growing incidence of obesity, physi-
al inactivity and alcohol consumption. Patients with known risk
actors, abnormal clinical and laboratory liver findings or altered
maging results can be screened for liver fibrosis. A reduced
epatic vein diameter and an elevated caudate-to-right-lobe ratio
re important early imaging findings indicative of liver fibro-
is. A CT fibrosis score, which combines these two variables,
as been shown to be the most accurate measure for predicting
irrhosis.
The simplest and least expensive approach to evaluate a sus-
ected liver fibrosis is sonographic elastography using either
ransient elastography (Fibroscan) or acoustic radiation force
mpulse (ARFI) elastography.
Advanced imaging methods using magnetic resonance imag-
ng such as MR elastography have been shown to be superior to
onographic elastography in the early stages of suspected liver
brosis and in patients who have medical conditions that pre-
lude the use of sonographic elastography (e.g., obese patients).
Other advantages of MR imaging techniques are their ability
o assess the entire liver and the lack of inter-rater variability
hat affects sonographic elastography or liver biopsies; for this
eason, MR elastography could replace liver biopsy as a new
iagnostic gold standard.onﬂict  of  interest
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[audate–right-lobe ratio (CRL). The sum of the three liver vein diameters (LD)
 and therefore compatible with liver cirrhosis.
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